Smart Biopsy Devices Market Report 2026

Smart Biopsy Devices Market Overview

• Smart Biopsy Devices market size has reached to $3.01 billion in 2025 • Expected to grow to $4.32 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: Surging Cancer Cases To Drive Market Growth • Market Trend: Innovative Multi-Modality Biopsy Markers Enhance Accuracy And Long-Term Visibility In Breast Cancer Diagnostics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Smart Biopsy Devices Market?

Smart biopsy devices refer to intelligent instruments intended to increase the precision and efficiency of tissue samples during medical procedures. It has features such as image guidance, real-time feedback, or robotic help to improve diagnostic capabilities and patient outcomes. It is used for diagnosing cancer and delivering therapeutic drugs. The main products of smart biopsy devices are needle-based biopsy instruments, procedure trays, localization wires, and others. Needle-based biopsy instruments refer to equipment that is used in a process to take a sample of your body's cells for laboratory analysis, which is used to collect tissue or liquid samples from bones, muscles, and other organs such as the liver and lungs. The guidance techniques include ultrasound-guided biopsy, stereotactic-guided biopsy, magnetic resonance imaging-guided biopsy, and others, that are used for various applications such as breast cancer, skin cancer, liver cancer, prostate cancer, and others. The end users are hospitals, academic and research institutes, diagnostic and imaging centers.

What Is The Smart Biopsy Devices Market Growth Forecast?

The smart biopsy devices market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing demand for precision oncology diagnostics, rising investments in smart surgical technologies, expansion of robotic-assisted intervention platforms, growing focus on early disease detection, increasing integration of AI-driven diagnostic support. Major trends in the forecast period include increasing adoption of image-guided biopsy systems, rising use of robotic-assisted biopsy procedures, growing integration of real-time tissue feedback technologies, expansion of minimally invasive diagnostic techniques, enhanced focus on diagnostic accuracy and patient safety.

Global Smart Biopsy Devices Market Segmentation

1) By Product: Needle-Based Biopsy Instruments, Localization Wires 2) By Guidance Technique: Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, Magnetic Resonance Imaging-Guided Biopsy, Other Guidance Techniques 3) By Application: Breast Cancer, Skin Cancer, Liver Cancer, Prostate Cancer, Other Applications 4) By End-User: Hospitals, Academic And Research Institutes, Diagnostic And Imaging Centers Subsegments: 1) By Needle-Based Biopsy Instruments: Core Needle Biopsy Devices, Fine Needle Aspiration (FNA) Devices, Vacuum-Assisted Biopsy Devices 2) By Localization Wires: Hook Wire Localization Devices, Radar Localization Devices, Magnetic Localization Devices

What Is The Driver Of The Smart Biopsy Devices Market?

The rising cancer cases are expected to propel the growth of the smart biopsy devices market going forward. Cancer is a broad category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. The rising number of cancer cases increased the need for precise and focused tissue samples. This has sparked the creation and advancement of smart biopsy instruments with better molecular, imaging, and precision capabilities to aid diagnosis and treatment planning. For instance, in January 2024, according to the World Health Organization, a Switzerland-based Intergovernmental organization, it is projected that there will be over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases and 9.7 million deaths recorded in 2022. Therefore, the rising cancer cases are driving the growth of the smart biopsy device industry.

Key Players In The Global Smart Biopsy Devices Market

Major companies operating in the smart biopsy devices market are Becton Dickinson and Company, Boston Scientific Corporation, Hologic Inc., Cook Medical Inc., Medtronic Plc, Olympus Corporation, B. Braun Melsungen AG, CONMED Corporation, FUJIFILM Holdings Corporation, Argon Medical Devices Inc., SOMATEX Medical Technologies GmbH, TSK Laboratory Europe B.V., INRAD Inc., Esaote SpA, Planmed Oy, Canon Medical Systems Corporation, Siemens Healthineers, General Electric Company, Intuitive Surgical Inc., Karl Storz SE And Co KG, Stryker Corporation

Global Smart Biopsy Devices Market Trends and Insights

Major companies operating in the smart biopsy devices market are focusing on developing advanced solutions, such as multi-modality breast biopsy markers, to improve lesion localization, enable long-term site visibility, and enhance diagnostic confidence. Multi-modality markers refer to specialized biopsy site markers engineered to remain clearly visible across ultrasound, mammography, and MRI, helping clinicians accurately track biopsy locations and support precise follow-up assessment. For instance, in March 2024, Mammotome, a U.S.-based medical technology company, launched LumiMARK, its next-generation 510(k)-cleared breast biopsy site marker designed for multi-modality identification. Available in three distinct 3D shapes—including Tulip™ and Rose™—the marker provides consistent visibility across imaging modalities and offers improved long-term detectability in both breast tissue and lymph nodes, supporting more accurate diagnosis and ongoing clinical decision-making.

What Are Latest Mergers And Acquisitions In The Smart Biopsy Devices Market?

In June 2023, Quest Diagnostics, a US-based medical laboratories company, acquired Haystack Oncology for $450 million. The acquisition of Haystack Oncology by Quest Diagnostics enhances the company's cancer diagnostics portfolio by incorporating Haystack's highly sensitive minimal-residual disease (MRD) testing technology based on circulating tumor DNA (ctDNA), enabling Quest to offer advanced blood-based clinical lab services for solid tumor cancers with improved early detection capabilities starting in 2024. Haystack Oncology Inc. is a US-based biotechnology company that specializes in developing and utilizing advanced technologies for minimal-residual disease (MRD) testing in the field of cancer diagnostics.

Regional Outlook

North America was the largest region in the smart biopsy devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the smart biopsy devices market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Smart Biopsy Devices Market?

The smart biopsy devices market consists of revenues earned by entities by providing services such as collecting biopsy samples, real-time cancer tissue characterization, minimally invasive biopsy, and precise tissue targeting. The market value includes the value of related goods sold by the service provider or included within the service offering. The smart biopsy devices market also includes sales of image-guided biopsy devices, core biopsy devices, bone biopsy needles and devices, and molecular biopsy devices which are used in providing collecting biopsy samples, real-time cancer tissue characterization services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.